for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,812.00GBp

Change

-30.00(-0.34%)

Volume

1,060,599

Today's Range

8,761.00

 - 

8,892.00

52 Week Range

6,499.80

 - 

9,523.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

French Drug Safety Agency Details Latest Study On COVID-19 Vaccines

Jan 18 (Reuters) - France's ansm drug safety agency: :FRENCH DRUG SAFETY REGULATOR ANSM SAYS STUDY CONFIRMS THE SAFETY OF MRNA COVID-19 VACCINES AGAINST THE RISK OF SERIOUS CARDIOVASCULAR EVENTS IN ADULTS.FRENCH DRUG SAFETY REGULATOR SAYS IN CONTRAST, ADENOVIRUS VACCINES APPEAR TO BE ASSOCIATED WITH A SLIGHT INCREASE IN THE RISK OF MYOCARDIAL INFARCTION AND PULMONARY EMBOLISM IN ADULTS WITHIN TWO WEEKS OF INJECTION.Related statement (in French): ANSM website. ((Tassilo.Hummel@thomsonreuters.com; +33 (0) 6 75 31 92 00;)).

EMA Recommends To Include Transverse Myelitis As Side Effect Of Vaxzevria and COVID-19 Vaccine Janssen

Jan 14 (Reuters) - AstraZeneca PLC <AZN.L>::EMA: MEETING HIGHLIGHTS FROM THE PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) 10 - 13 JANUARY 2022: 14/01/2022.EMA: HAS STARTED A REVIEW OF MEDICINES THAT CONTAIN TERLIPRESSIN.EMA: PRAC RECOMMENDED CHANGE TO PRODUCT INFORMATION FOR VAXZEVRIA, COVID-19 VACCINE JANSSEN TO INCLUDE WARNING TO RAISE AWARENESS OF VERY RARE CASES OF TM FOLLOWING VACCINATION.EMA SAYS ON VAXZEVRIA, FEWER CASES OF THROMBOSIS WITH THROMBOCYTOPENIA REPORTED AFTER SECOND DOSE.EMA: PRAC CONCLUDED THAT CAUSAL RELATIONSHIP BETWEEN VAXZEVRIA AND COVID-19 VACCINE JANSSEN AND TRANSVERSE MYELITIS IS AT LEAST REASONABLE POSSIBILITY.EMA-PRAC RECOMMENDED UPDATING PRODUCT INFO FOR VAXZEVRIA TO ADD MORE INFO ABOUT VERY RARE CASES OF THROMBOSIS WITH TTS OCCURRED FOLLOWING VACCINATION.EMA SAYS A RECENT REVIEW OF AVAILABLE SAFETY DATA HAS CONCLUDED ON AN INCREASED RISK FOR LIVER INJURY FOLLOWING TREATMENT WITH MAVENCLAD .

Fusion Pharma Nominates First Targeted Alpha Therapy Candidate In Collaboration With Astrazeneca For Ind-Enabling Studies

Jan 10 (Reuters) - AstraZeneca PLC <AZN.L>::FUSION PHARMACEUTICALS ANNOUNCES NOMINATION OF FIRST TARGETED ALPHA THERAPY CANDIDATE IN COLLABORATION WITH ASTRAZENECA TO ADVANCE INTO IND-ENABLING STUDIES FOR PHASE 1 DEVELOPMENT.FUSION PHARMACEUTICALS INC - CO, ASTRAZENECA WILL SHARE COSTS EQUALLY THROUGH CLINICAL DEVELOPMENT.FUSION PHARMACEUTICALS INC - IND ENABLING STUDIES ARE ONGOING.

AstraZeneca And Neurimmune Sign Deal For NI006

Jan 7 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006.ASTRAZENECA: ASTRAZENECA AND NEURIMMUNE SIGN EXCLUSIVE GLOBAL COLLABORATION AND LICENCE AGREEMENT TO DEVELOP AND COMMERCIALISE NI006.ASTRAZENECA - ASTRAZENECA AND NEURIMMUNE SIGN EXCLUSIVE GLOBAL COLLABORATION AND LICENCE AGREEMENT TO DEVELOP AND COMMERCIALISE NI006.ASTRAZENECA - INVESTIGATIONAL HUMAN MONOCLONAL ANTIBODY IN PHASE IB DEVELOPMENT FOR TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, A SYSTEMIC, PROGRESSIVE AND FATAL CONDITION.ASTRAZENECA - UNDER AGREEMENT, ALEXION WILL BE GRANTED AN EXCLUSIVE WORLDWIDE LICENCE TO DEVELOP, MANUFACTURE AND COMMERCIALISE NI006..ASTRAZENECA - ALEXION WILL PAY NEURIMMUNE AN UPFRONT PAYMENT OF $30M.ASTRAZENECA - POTENTIAL FOR ADDITIONAL CONTINGENT MILESTONE PAYMENTS OF UP TO $730M UPON ACHIEVEMENT OF CERTAIN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ASTRAZENECA - NEURIMMUNE WILL CONTINUE TO BE RESPONSIBLE FOR COMPLETION OF CURRENT PHASE IB CLINICAL TRIAL ON BEHALF OF ALEXION.

AstraZeneca and Ionis Close Agreement To Develop And Commercialise eplontersen

Dec 29 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL.ASTRAZENECA PLC - ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL.ASTRAZENECA - UNDER TERMS OF AGREEMENT, UPFRONT PAYMENT FROM ASTRAZENECA TO IONIS IS $200M.ASTRAZENECA - ASTRAZENECA WILL MAKE ADDITIONAL CONDITIONAL PAYMENTS OF UP TO $485M FOLLOWING REGULATORY APPROVALS..ASTRAZENECA - IT WILL ALSO PAY UP TO $2.9BN OF SALES-RELATED MILESTONES BASED ON SALES THRESHOLDS BETWEEN $500M AND $6BN.ASTRAZENECA - TRANSACTION DOES NOT IMPACT ASTRAZENECA'S FINANCIAL GUIDANCE FOR 2021..ASTRAZENECA - COLLABORATION INCLUDES TERRITORY-SPECIFIC DEVELOPMENT, COMMERCIAL AND MEDICAL AFFAIRS COST-SHARING PROVISIONS..

AstraZeneca Says Evusheld Long-Acting Antibody Combo Retains Neutralising Activity Against Omicron

Dec 23 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA - EVUSHELD LONG-ACTING ANTIBODY COMBO RETAINS NEUTRALISING ACTIVITY AGAINST OMICRON VARIANT IN STUDIES FROM OXFORD AND WASHINGTON UNIVERSITIES.ASTRAZENECA - DATA WERE GENERATED FROM LABORATORY TESTING USING ACTUAL LIVE VIRUS ISOLATED FROM INDIVIDUALS WHO CONTRACTED OMICRON VARIANT OF COVID-19.ASTRAZENECA - FINDINGS ARE IN LINE WITH PSEUDOVIRUS NEUTRALISING DATA FROM INDEPENDENT INVESTIGATORS AT US FOOD AND DRUG ADMINISTRATION.ASTRAZENECA - CONTINUING TO COLLECT FURTHER DATA TO BETTER UNDERSTAND IMPLICATIONS OF THESE DATA IN CLINICAL PRACTICE.

AstraZeneca Plc Says Ultomiris Accepted For FDA Priority Review For gMG

Dec 21 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG.ASTRAZENECA - ULTOMIRIS REGULATORY SUBMISSION ACCEPTED UNDER FDA PRIORITY REVIEW IN US FOR ADULTS WITH GENERALISED MYASTHENIA GRAVIS.ASTRAZENECA - ULTOMIRIS REGULATORY SUBMISSION ACCEPTED UNDER FDA PRIORITY REVIEW IN US FOR ADULTS WITH GENERALISED MYASTHENIA GRAVIS.ASTRAZENECA - SUBMISSION BASED ON POSITIVE PHASE III TRIAL IN WHICH ULTOMIRIS SIGNIFICANTLY IMPROVED FUNCTIONAL ACTIVITIES.ASTRAZENECA - FDA SET A PRESCRIPTION DRUG USER FEE ACT DATE DURING Q2 OF 2022.

AstraZeneca Says Saphnelo Recommended For EU Approval For Systemic Lupus Erythematosus

Dec 20 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE.ASTRAZENECA - SAPHNELO IS A FIRST-IN-CLASS TYPE I INTERFERON RECEPTOR ANTIBODY SHOWN TO REDUCE OVERALL DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.ASTRAZENECA - SAPHNELO RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

Amgen Says FDA Approved Tezspire In The U.S. For Severe Asthma

Dec 17 (Reuters) - Amgen Inc <AMGN.O>::FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA.AMGEN -FDA) APPROVED CO, ASTRAZENECA'S TEZSPIRE FOR ADD-ON MAINTENANCE TREATMENT OF ADULT, PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH SEVERE ASTHMA.

AstraZeneca Says Evusheld Long-Acting Antibody Combination Retains Neutralising Activity Against Omicron Variant In Independent FDA Study

Dec 16 (Reuters) - AstraZeneca PLC <AZN.L>::EVUSHELD LONG-ACTING ANTIBODY COMBINATION RETAINS NEUTRALISING ACTIVITY AGAINST OMICRON VARIANT IN INDEPENDENT FDA STUDY.ASTRAZENECA - CONTINUING TO COLLECT FURTHER DATA TO BETTER UNDERSTAND IMPLICATIONS OF THIS OBSERVATION IN CLINICAL PRACTICE..ASTRAZENECA - OMICRON VARIANT WAS NOT IN CIRCULATION DURING THE EVUSHELD CLINICAL TRIALS..ASTRAZENECA - MORE ANALYSES TO EVALUATE EVUSHELD AGAINST OMICRON VARIANT ARE BEING CONDUCTED BY ASTRAZENECA AND THIRD-PARTY LABORATORIES.ASTRAZENECA - EARLY DATA WAS GENERATED BY PSEUDOVIRUS TESTING OF FULL OMICRON VARIANT SPIKE AGAINST COMBINATION OF TIXAGEVIMAB WITH CILGAVIMAB.ASTRAZENECA - ADDITIONAL ANALYSES TO EVALUATE EVUSHELD AGAINST OMICRON VARIANT CONDUCTED WITH DATA ANTICIPATED VERY SOON..Further company coverage: AZN.L. ((Reuters.Briefs@thomsonreuters.com;)).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up